The 36-month beta value for OMER is also noteworthy at 2.25. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for OMER is 55.98M, and at present, short sellers hold a 23.39% of that float. The average trading volume of OMER on July 03, 2025 was 1.05M shares.
OMER) stock’s latest price update
Omeros Corporation (NASDAQ: OMER) has seen a rise in its stock price by 4.04% in relation to its previous close of $2.97. However, the company has experienced a -11.71% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-06-27 that SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The MAA includes response-based analyses in narsoplimab-treated TA-TMA patients as well as analyses comparing overall survival between narsoplimab-treated patients and a well-matched external con.
OMER’s Market Performance
Omeros Corporation (OMER) has seen a -11.71% fall in stock performance for the week, with a 0.32% gain in the past month and a -60.94% plunge in the past quarter. The volatility ratio for the week is 8.28%, and the volatility levels for the past 30 days are at 8.12% for OMER. The simple moving average for the past 20 days is -8.16% for OMER’s stock, with a -53.56% simple moving average for the past 200 days.
Analysts’ Opinion of OMER
Many brokerage firms have already submitted their reports for OMER stocks, with H.C. Wainwright repeating the rating for OMER by listing it as a “Buy.” The predicted price for OMER in the upcoming period, according to H.C. Wainwright is $9 based on the research report published on June 10, 2025 of the current year 2025.
D. Boral Capital, on the other hand, stated in their research note that they expect to see OMER reach a price target of $36. The rating they have provided for OMER stocks is “Buy” according to the report published on December 23rd, 2024.
Rodman & Renshaw gave a rating of “Buy” to OMER, setting the target price at $9 in the report published on November 14th of the previous year.
OMER Trading at -29.26% from the 50-Day Moving Average
After a stumble in the market that brought OMER to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.28% of loss for the given period.
Stock Fundamentals for OMER
Current profitability levels for the company are sitting at:
- -400.95 for the present operating margin
- -0.5 for the gross margin
The net margin for Omeros Corporation stands at -371.58. The total capital return value is set at -1.09.
Based on Omeros Corporation (OMER), the company’s capital structure generated -1.17 points at debt to capital in total, while cash flow to debt ratio is standing at -1.24. The debt to equity ratio resting at -0.54. The interest coverage ratio of the stock is -12.92.
Currently, EBITDA for the company is -157.0 million with net debt to EBITDA at -0.71. When we switch over and look at the enterprise to sales, we see a ratio of 709.01. The receivables turnover for the company is 0.0for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.16.
Conclusion
In summary, Omeros Corporation (OMER) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
